Adaptive Operating Income from 2010 to 2024

ADPT Stock

USD 5.94 0.21 3.66%

Adaptive Biotechnologies Operating Income yearly trend continues to be comparatively stable with very little volatility. Operating Income is likely to outpace its year average in 2024. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Adaptive Biotechnologies Corp generates from its operations. View All Fundamentals

Operating Income

First Reported

2018-03-31

Previous Quarter

-39.4 M

Current Value

-32.6 M

Quarterly Volatility

16.2 M

Covid

Check Adaptive Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adaptive Biotechnologies' main balance sheet or income statement drivers, such as Interest Income of 14.2 M, Discontinued Operations of 0.0 or Depreciation And Amortization of 13.1 M, as well as many indicators such as Price To Sales Ratio of 3.95, Dividend Yield of 0.0 or PTB Ratio of 2.41. Adaptive financial statements analysis is a perfect complement when working with Adaptive Biotechnologies Valuation or Volatility modules.

Check out the analysis of Adaptive Biotechnologies Correlation against competitors.

Latest Adaptive Biotechnologies' Operating Income Growth Pattern

Below is the plot of the Operating Income of Adaptive Biotechnologies Corp over the last few years. Operating Income is the amount of profit realized from Adaptive Biotechnologies operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Adaptive Biotechnologies Corp is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Adaptive Biotechnologies' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Adaptive Biotechnologies' overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Adaptive Operating Income Regression Statistics

	Arithmetic Mean	(99,242,283)
	Coefficient Of Variation	(77.05)
	Mean Deviation	67,796,778
	Median	(44,475,000)
	Standard Deviation	76,470,333
	Sample Variance	5847.7T
	Range	182.6M
	R-Value	(0.86)
	Mean Square Error	1615T
	R-Squared	0.74
	Significance	0.000035
	Slope	(14,744,556)
	Total Sum of Squares	81868T

Adaptive Operating Income History

	2024	-215.7 M
	2023	-227 M
	2022	-200.2 M
	2021	-209 M
	2020	-152.8 M
	2019	-78.4 M
	2018	-49.8 M

Other Fundumenentals of Adaptive Biotechnologies

Non Operating Income Net Other

Adaptive Biotechnologies Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Good Will	Short Term Investments	Long Term Debt Total	Capital Surpluse	Total Liab	Net Invested Capital	Long Term Investments	Total Current Assets	Net Working Capital	Intangible Assets	Common Stock	Property Plant Equipment	Capital Stock
Total Assets		0.99	0.97	0.98	0.52	-0.64	0.61	-0.37	0.56	-0.27	0.93	0.92	0.89	-0.93	0.99	0.67	0.97	0.93	-0.77	0.92	0.66	0.92
Total Stockholder Equity	0.99		0.99	0.99	0.54	-0.67	0.66	-0.38	0.61	-0.27	0.91	0.94	0.93	-0.96	1.0	0.68	0.95	0.91	-0.81	0.95	0.72	0.95
Net Tangible Assets	0.97	0.99		0.98	0.61	-0.72	0.72	-0.42	0.68	-0.31	0.9	0.96	0.96	-0.97	0.99	0.64	0.94	0.89	-0.86	0.98	0.77	0.98
Current Deferred Revenue	0.98	0.99	0.98		0.56	-0.71	0.66	-0.39	0.64	-0.28	0.85	0.94	0.93	-0.96	0.99	0.7	0.91	0.85	-0.84	0.95	0.77	0.95
Net Debt	0.52	0.54	0.61	0.56		-0.95	0.77	-0.93	0.77	-0.88	0.49	0.78	0.72	-0.72	0.54	-0.05	0.51	0.46	-0.86	0.72	0.74	0.75
Retained Earnings	-0.64	-0.67	-0.72	-0.71	-0.95		-0.87	0.8	-0.9	0.74	-0.55	-0.86	-0.85	0.81	-0.67	-0.11	-0.59	-0.52	0.96	-0.83	-0.9	-0.86
Accounts Payable	0.61	0.66	0.72	0.66	0.77	-0.87		-0.53	0.98	-0.45	0.64	0.81	0.85	-0.75	0.66	0.02	0.65	0.6	-0.9	0.83	0.85	0.83
Long Term Debt	-0.37	-0.38	-0.42	-0.39	-0.93	0.8	-0.53		-0.52	0.99	-0.35	-0.64	-0.49	0.58	-0.38	0.12	-0.37	-0.33	0.65	-0.51	-0.48	-0.56
Net Receivables	0.56	0.61	0.68	0.64	0.77	-0.9	0.98	-0.52		-0.44	0.53	0.77	0.84	-0.71	0.61	0.03	0.56	0.49	-0.91	0.8	0.91	0.8
Good Will	-0.27	-0.27	-0.31	-0.28	-0.88	0.74	-0.45	0.99	-0.44		-0.25	-0.54	-0.38	0.48	-0.27	0.21	-0.26	-0.23	0.55	-0.4	-0.39	-0.45
Short Term Investments	0.93	0.91	0.9	0.85	0.49	-0.55	0.64	-0.35	0.53	-0.25		0.85	0.8	-0.83	0.91	0.43	0.99	1.0	-0.68	0.84	0.5	0.84
Long Term Debt Total	0.92	0.94	0.96	0.94	0.78	-0.86	0.81	-0.64	0.77	-0.54	0.85		0.96	-0.99	0.94	0.47	0.89	0.84	-0.93	0.98	0.82	0.99
Capital Surpluse	0.89	0.93	0.96	0.93	0.72	-0.85	0.85	-0.49	0.84	-0.38	0.8	0.96		-0.95	0.93	0.49	0.85	0.78	-0.96	1.0	0.91	0.99
Total Liab	-0.93	-0.96	-0.97	-0.96	-0.72	0.81	-0.75	0.58	-0.71	0.48	-0.83	-0.99	-0.95		-0.96	-0.58	-0.87	-0.82	0.89	-0.97	-0.8	-0.98
Net Invested Capital	0.99	1.0	0.99	0.99	0.54	-0.67	0.66	-0.38	0.61	-0.27	0.91	0.94	0.93	-0.96		0.68	0.95	0.91	-0.81	0.95	0.72	0.95
Long Term Investments	0.67	0.68	0.64	0.7	-0.05	-0.11	0.02	0.12	0.03	0.21	0.43	0.47	0.49	-0.58	0.68		0.5	0.46	-0.3	0.52	0.35	0.5
Total Current Assets	0.97	0.95	0.94	0.91	0.51	-0.59	0.65	-0.37	0.56	-0.26	0.99	0.89	0.85	-0.87	0.95	0.5		0.99	-0.73	0.88	0.57	0.88
Net Working Capital	0.93	0.91	0.89	0.85	0.46	-0.52	0.6	-0.33	0.49	-0.23	1.0	0.84	0.78	-0.82	0.91	0.46	0.99		-0.65	0.83	0.47	0.83
Intangible Assets	-0.77	-0.81	-0.86	-0.84	-0.86	0.96	-0.9	0.65	-0.91	0.55	-0.68	-0.93	-0.96	0.89	-0.81	-0.3	-0.73	-0.65		-0.94	-0.95	-0.95
Common Stock	0.92	0.95	0.98	0.95	0.72	-0.83	0.83	-0.51	0.8	-0.4	0.84	0.98	1.0	-0.97	0.95	0.52	0.88	0.83	-0.94		0.87	1.0
Property Plant Equipment	0.66	0.72	0.77	0.77	0.74	-0.9	0.85	-0.48	0.91	-0.39	0.5	0.82	0.91	-0.8	0.72	0.35	0.57	0.47	-0.95	0.87		0.87
Capital Stock	0.92	0.95	0.98	0.95	0.75	-0.86	0.83	-0.56	0.8	-0.45	0.84	0.99	0.99	-0.98	0.95	0.5	0.88	0.83	-0.95	1.0	0.87

Click cells to compare fundamentals

About Adaptive Biotechnologies Financial Statements

Adaptive Biotechnologies shareholders use historical fundamental indicators, such as Operating Income, to determine how well the company is positioned to perform in the future. Although Adaptive Biotechnologies investors may analyze each financial statement separately, they are all interrelated. The changes in Adaptive Biotechnologies' assets and liabilities, for example, are also reflected in the revenues and expenses on on Adaptive Biotechnologies' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Operating Income	-227 M	-215.7 M
Non Operating Income Net Other	3.7 M	3.3 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Adaptive Stock Analysis

When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Adaptive Operating Income from 2010 to 2024

Latest Adaptive Biotechnologies' Operating Income Growth Pattern

Adaptive Operating Income Regression Statistics

Adaptive Operating Income History

Other Fundumenentals of Adaptive Biotechnologies

Adaptive Biotechnologies Operating Income component correlations

About Adaptive Biotechnologies Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Adaptive Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY